Strategic Focus Clinical-stage biopharma targeting chronic cough in IPF, non-IPF ILD, and RCC presents opportunities to engage healthcare providers, payers, and patient advocacy groups focused on respiratory diseases and fibrosis treatments.

Financing Momentum Recent $173 million financing and ongoing investor events signal buoyant investor interest and potential for strategic partnerships, licensing discussions, or favorable terms for collaborations around Haduvio.

Clinical Validation Haduvio has demonstrated a statistically significant reduction in cough frequency in IPF chronic cough and RCC trials, highlighting a differentiated mechanism (KAMA) that could drive physician adoption and guide payer value discussions.

Engagement Pipeline Active participation in major conferences and investor days indicates opportunities to coordinate co-marketing, thought leadership, and sponsor-physician education programs to boost awareness and enrollment.

Strategic Partnerships Leadership activities, new CFO appointment, and visibility at industry events position Trevi for potential collaborations with larger biotech/pharma players for co-development, licensing, or commercialization support.